PI3K 抑制剂林普利塞对弥漫大B 细胞淋巴瘤的体外抗肿瘤效应
张凯敏， 黄玉洁， 段莹， 郭宝平， 柯晴， 廖成成… - 中国癌症防治杂志, 2024 - zgazfz.com
目的探讨PI3K 抑制剂林普利塞(Linperlisib, YY⁃ 20394) 对弥漫大B 细胞淋巴瘤(diffuse large
B⁃ cell lymphoma, DLBCL) 的体外抗肿瘤效应及其作用机制. 方法采用CCK⁃ 8 …
B⁃ cell lymphoma, DLBCL) 的体外抗肿瘤效应及其作用机制. 方法采用CCK⁃ 8 …
PI3K-p110σ 抑制剂联合硼替佐米对套细胞淋巴瘤细胞增殖和凋亡的影响及其机制
屈福莲， 夏冰， 李晓武， 郭姗琦， 张乐… - Chinese Journal of …, 2015 - search.ebscohost.com
目的探讨PI3K⁃ p110σ 抑制剂CAL⁃ 101 联合硼替佐米(BTZ) 对人套细胞淋巴瘤(MCL)
细胞株增殖和凋亡的影响及其作用机制. 方法以不同浓度的CAL⁃ 101 和BTZ 分别处理MCL …
细胞株增殖和凋亡的影响及其作用机制. 方法以不同浓度的CAL⁃ 101 和BTZ 分别处理MCL …
PI3Kδ 抑制剂CAL-101 对淋巴瘤细胞系Raji 和SUDHL-10 的作用及其机制研究
王亚非， 夏冰， 屈福莲， 李晓武， 郭姗琦， 袁田， 赵伟鹏… - 中国肿瘤临床, 2015 - cjco.cn
目的: 探讨PI 3Kδ 抑制剂CAL-101 对弥漫大B 细胞淋巴瘤细胞系SUDHL-10 和Burkitt
淋巴瘤细胞系Raji 的作用及其相关机制, 为这类疾病的治疗提供新的思路. 方法 …
淋巴瘤细胞系Raji 的作用及其相关机制, 为这类疾病的治疗提供新的思路. 方法 …
SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL
L Fan, C Wang, Z Wang, X Zhang, L Cao, Y Miao, X Du… - 2019 - ashpublications.org
Introduction: PI3Kδ, one of the class I PI3Ks, is found expressed primarily in leukocytes and
plays an essential role in B-cell development and function. Here, we comprehensively …
plays an essential role in B-cell development and function. Here, we comprehensively …
Safety and efficacy of TQ-B3525, a novel and selective oral PI3K α/δ inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and …
H Wang, W Jiang, S Li, Y Wang, P Sun, P Zhou… - 2020 - ascopubs.org
8058 Background: TQ-B3525 is a novel and selective oral PI3K α/δ inhibitor with activity 41
and 138 folds higher than Buparlisib against PI3K α and PI3K δ in pre-clinical research. This …
and 138 folds higher than Buparlisib against PI3K α and PI3K δ in pre-clinical research. This …
[PDF][PDF] 利妥昔单抗治疗弥漫大B 细胞淋巴瘤的临床观察
王志军， 吴月兵 - 肿瘤防治研究, 2011 - zlfzyj.com
利妥昔单抗治疗弥漫大R细胞淋巴瘤的临床观察 Page 1 !"#!!"$#$%!"%$&''($!""")&'%&$("!!$"&$"(*
收稿В期("!")"%)($ 修回В期("!!)"#)"& 作者单位*#""%$武汉湖北省肿瘤医院肿瘤内科 通信作者吴 …
收稿В期("!")"%)($ 修回В期("!!)"#)"& 作者单位*#""%$武汉湖北省肿瘤医院肿瘤内科 通信作者吴 …
RETRACTED: BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma
J Li, C Qian, Q Zhou, J Li, K Li, P Yi - 2017 - Elsevier
hi a ine, hina Accepted 25 July 2017 Vorinostat (PubChem CID: 5311) Idelalisib (PubChem
CID: 11625818) Keywords: gene lar researchers to target both PI3K and HDAC. We …
CID: 11625818) Keywords: gene lar researchers to target both PI3K and HDAC. We …
SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis
W Qi, A Stejskal, C Morales… - Journal of …, 2012 - utsouthwestern.elsevierpure.com
The PI3K pathway is activated in a variety of human tumors including B-cell Non Hodgkin
Lymphoma (B-NHL). Targeting this pathway has been validated in solid tumors, leukemia …
Lymphoma (B-NHL). Targeting this pathway has been validated in solid tumors, leukemia …
Amdizalisib (HMPL-689), a highly selective PI3Kδ inhibitor, exhibits potent anti-tumor activity in pre-clinical B-cell lymphoma models
J Hu, J Wang, X Dai, J He, J Liang, Y Yu, J Yu, N Yang… - Cancer Research, 2022 - AACR
Background: The delta isoform of PI3K (PI3Kδ) plays an important role in B-cell development
and function by mediating the signaling of key receptors on B cells. Aberrant activation of …
and function by mediating the signaling of key receptors on B cells. Aberrant activation of …